Results 181 to 190 of about 49,408 (198)

The β‐Lactams Strike Back: Ceftazidime‐Avibactam

Pharmacotherapy, 2015
Evan Zasowski, Jeffrey M Rybak
exaly  

Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

Antimicrobial Agents and Chemotherapy, 2020
Christopher Polk, Danya Roshdy
exaly  

Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota

International Journal of Antimicrobial Agents, 2015
Staffan Rosenborg, Georgios Panagiotidis, Andrej Weintraub   +2 more
exaly  

Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China

Clinical Microbiology and Infection, 2020
Xueqing Wu, Murat áková
exaly  

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

International Journal of Antimicrobial Agents, 2017
Greg Stone, Min Ja Kim, Peter Laud
exaly  

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

Clinical Infectious Diseases, 2016
Greg Stone, Florian Wagenlehner, Jack Sobel   +2 more
exaly  

Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo

Journal of Antimicrobial Chemotherapy, 2019
Stephan Göttig, Michael Hogardt, Thomas Wichelhaus   +2 more
exaly  

Ceftazidime

2021
openaire   +1 more source

In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens

Antimicrobial Agents and Chemotherapy, 2017
Greg Stone, Patricia Bradford, Paul Newell   +2 more
exaly  

Ceftazidim

2013
openaire   +1 more source